These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1597239)

  • 41. (131)I treatment in Differentiated Thyroid Cancer and End-Stage Renal Disease.
    Ortega AJ; Vázquez RG; Cuenca JI; Brocca MA; Castilla J; Martínez JM; González EN
    Rev Esp Med Nucl Imagen Mol; 2016; 35(1):29-33. PubMed ID: 26144699
    [TBL] [Abstract][Full Text] [Related]  

  • 42. DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy.
    Eberlein U; Scherthan H; Bluemel C; Peper M; Lapa C; Buck AK; Port M; Lassmann M
    J Nucl Med; 2016 Feb; 57(2):173-9. PubMed ID: 26564321
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radioiodine treatment for malignant thyroid disease.
    Berg G
    Acta Oncol; 2006; 45(8):1041-5. PubMed ID: 17118836
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry.
    Yeung HW; Humm JL; Larson SM
    J Nucl Med; 2000 Jun; 41(6):1082-5. PubMed ID: 10855639
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer.
    Verburg FA; Hänscheid H; Luster M
    Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):279-290. PubMed ID: 28911724
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Radioiodine therapy of differentiated thyroid cancer. Recommendations of the Therapy Study Group of the German Society of Nuclear Medicine].
    Georgi P; Emrich D; Heidenreich P; Moser E; Reiners C; Schicha H
    Nuklearmedizin; 1992 Aug; 31(4):151-3. PubMed ID: 1518724
    [No Abstract]   [Full Text] [Related]  

  • 47. Radioactive iodine in thyroid medicine--how it started in Sweden and some of today's challenges.
    Mattsson S; Johansson L; Jönsson H; Nosslin B
    Acta Oncol; 2006; 45(8):1031-6. PubMed ID: 17118834
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fractionated dosage of radioiodine for the ablation of differentiated thyroid carcinoma.
    Czepczyński R; Ziemnicka K; Baczyk M; Oleksa R; Ruchała M; Sowiński J
    Thyroid; 2005 Nov; 15(11):1261-5. PubMed ID: 16356090
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Agreements and discrepancies in radioiodine therapy of differentiated thyroid cancer. 2d Heidelberg Meeting of Nuclear Medicine Practitioners on 1.2.91].
    Nuklearmedizin; 1992 Aug; 31(4):145-50. PubMed ID: 1355598
    [No Abstract]   [Full Text] [Related]  

  • 50. A study of the time of hospital discharge of differentiated thyroid cancer patients after receiving iodine-131 for thyroid remnant ablation treatment.
    Azizmohammadi Z; Tabei F; Shafiei B; Babaei AA; Jukandan SM; Naghshine R; Javadi H; Nabipour I; Assadi M; Asli IN
    Hell J Nucl Med; 2013; 16(2):103-6. PubMed ID: 23687641
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiation exposure for 'caregivers' during high-dose outpatient radioiodine therapy.
    Marriott CJ; Webber CE; Gulenchyn KY
    Radiat Prot Dosimetry; 2007; 123(1):62-7. PubMed ID: 16825250
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radioiodide (131I) therapy for the treatment of canine thyroid carcinoma.
    Worth AJ; Zuber RM; Hocking M
    Aust Vet J; 2005 Apr; 83(4):208-14. PubMed ID: 15907038
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of different dosimetric methods for red marrow absorbed dose calculation in thyroid cancer therapy.
    Willegaignon J; Sapienza MT; Buchpiguel CA
    Radiat Prot Dosimetry; 2012 Apr; 149(2):138-46. PubMed ID: 21586539
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Radioiodine therapy for thyroid cancer in the era of risk stratification and alternative targeted therapies.
    Pryma DA; Mandel SJ
    J Nucl Med; 2014 Sep; 55(9):1485-91. PubMed ID: 25134528
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma.
    Reiners C; Biko J; Haenscheid H; Hebestreit H; Kirinjuk S; Baranowski O; Marlowe RJ; Demidchik E; Drozd V; Demidchik Y
    J Clin Endocrinol Metab; 2013 Jul; 98(7):3039-48. PubMed ID: 23616148
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma.
    Luster M; Sherman SI; Skarulis MC; Reynolds JR; Lassmann M; Hänscheid H; Reiners C
    Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1371-7. PubMed ID: 12856155
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Absence of bone marrow toxicity in elderly patients treated with recombinant human thyroid-stimulating hormone and empirically dosed radioiodine for thyroid cancer.
    Amdur RJ; Dan T; Mazzaferri E
    Am J Clin Oncol; 2013 Aug; 36(4):348-53. PubMed ID: 22547013
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Radiation Dose-rate Reduction Pattern in Well-differentiated Thyroid Cancer Treated with I-131.
    Khan SA; Khan MS; Arif M; Durr-e-Sabih ; Rahim MK; Ahmad I
    J Coll Physicians Surg Pak; 2015 Jul; 25(7):510-3. PubMed ID: 26208555
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 131I Biokinetics and cytogenetic dose estimates in ablation treatment of thyroid carcinoma.
    Nascimento AC; Lipsztein JL; Corbo R; Rebelo AM
    Health Phys; 2010 Oct; 99(4):457-63. PubMed ID: 20838086
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Shielding effect of distance in (131)I-131 therapy for differentiated thyroid cancer].
    Chi X; Liu F; Li G; Wang Q; Deng Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Feb; 34(2):286-8. PubMed ID: 24589615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.